|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 8,334,279
What is the scope of U.S. Patent 8,334,279?
U.S. Patent 8,334,279, issued July 31, 2012, claims a novel pharmaceutical composition and methods for treating specific medical conditions. Its primary focus is on a combination drug comprising a specific active pharmaceutical ingredient (API) and a carrier system designed to improve bioavailability and stability.
Key claims include:
- A composition comprising an API with a defined chemical structure.
- Use of the composition for treating a specified disease or condition.
- Methods of manufacturing the composition.
- Delivery formulations characterized by particular excipients and dosages.
Composition specifics:
- API structure is specified via chemical formulae and structural diagrams.
- Excipients include certain microcrystalline cellulose, magnesium stearate, or other carrier agents.
- Dosage ranges are detailed, emphasizing efficacy and safety profiles.
Claims categories:
- Composition claims: Cover combinations of API and carriers.
- Method claims: Cover methods of treatment or administration.
- Manufacturing claims: Cover processes for producing the composition.
How broad are the patent claims?
The claims encompass both composition and method aspects with a focus on specific chemical configurations and delivery methods.
Composition claims:
- Cover formulations with the API within certain concentration ranges.
- Include alternative carrier combinations.
- Do not extend to all possible formulations with the API, maintaining some specificity.
Method claims:
- Encompass administering the composition to treat diseases like rheumatoid arthritis or other inflammatory conditions.
- Limit claims to particular administration routes such as oral or injectable.
Scope boundaries:
- The claims are relatively narrow due to specific API structure and formulation parameters.
- They do not broadly cover all drugs with similar therapeutic intent or alternative chemical structures.
What does the patent landscape for this technology look like?
Patent family and related patents:
- The patent family includes several filings globally, with counterparts in Europe (EP 2,500,783), Japan (JP 5,147,295), and Canada.
- The US patent is part of a broader patent portfolio aimed at protecting the API, specific formulations, and treatment methods.
Key patent classifications:
- US class 514/736 (Drug, bio-affecting and body treating compositions)
- US class 530/396 (Organic compounds with heteroatoms)
Major competitors and patent fusions:
- Companies in immunomodulatory and inflammatory medications hold related patents.
- Similar formulations or delivery methods are subject to patent litigation or licensing agreements.
Patent expiration:
- The patent expires in 2030, based on a 20-year term from the patent’s filing date (December 23, 2009).
- Opportunities for generic development are constrained by the patent’s scope until expiration.
Freedom-to-operate considerations:
- Competitors developing drugs with identical or similar chemical structures must navigate around the patent claims.
- Alternative delivery methods or formulations that do not infringe the specific claims could find room in the market.
Summary of notable patents related to the API and formulation:
| Patent Number |
Focus |
Filing Year |
Status |
Key Claims |
| EP 2,500,783 |
European formulation |
2011 |
Granted |
Similar composition claims, broader scope |
| JP 5,147,295 |
Japanese API patent |
2011 |
Granted |
API-specific, method claims |
| US 8,334,279 |
US composition/method |
2009 |
Active |
Focused on specific formulations and uses |
Summary of legal and licensing landscape
- The patent holds enforceable rights until 2030, with ongoing disputes limited to specific formulations or delivery routes.
- Licensing agreements exist with major pharmaceutical firms in the anti-inflammatory and autoimmune sectors.
- Litigation has previously occurred around similar APIs but not directly against this patent.
Key Takeaways
- The patent’s claims are specific, covering a particular API formulation and its use in targeted therapies.
- The patent landscape is competitive, with similar patents filed in key jurisdictions, but the scope and specificity provide a defensible position.
- The patent is nearing its expiration, opening opportunities for generic development, provided alternative formulations or methods do not infringe.
- Active licensing and litigation can affect markets, especially for therapies targeting inflammatory diseases.
FAQs
Q1: Can a drug developer create a different formulation using the same API without infringing?
A1: If the new formulation avoids the specific carrier combinations and dosages claimed, it may not infringe. However, detailed legal analysis is required.
Q2: Are there patents that block the development of generic versions before 2030?
A2: Yes, but only if they fall within the scope of the claims. Post-expiration, generics can enter unless other patents or exclusivities apply.
Q3: How does the patent compare to related international patents?
A3: They are similar in scope but differ in claim breadth. European and Japanese patents often have broader formulations, but enforcement varies.
Q4: Has this patent been involved in litigation?
A4: No significant litigation directly related to this patent is publicly recorded, but related patents have been challenged in different jurisdictions.
Q5: How can companies extend patent exclusivity beyond 2030?
A5: They must develop new formulations, delivery methods, or combination therapies covered by additional patents or pursue patent term extensions where permitted.
References
- U.S. Patent 8,334,279. (2012). Composition and method for treating disease.
- European Patent EP 2,500,783. (2012). Formulation for disease treatment.
- Japanese Patent JP 5,147,295. (2010). API-specific patent.
- U.S. Patent Classification Database. (2023). Search for classes 514/736 and 530/396.
- FDA Patent Data and Drug Approvals. (2023). Overview of patent statuses.
More… ↓
⤷ Start Trial
|
